Combined Hormonal Contraception Study Notes
Combined Hormonal Contraception (CHC) Overview and Active Components
Definition & Composition:
- Combined Hormonal Contraception (CHC) consists of estrogen-progestin combination products.
- Synthetic Estrogen Component: Ethinyl estradiol.
- Progestin Component: Variable generations of progestin compounds.
Primary Purpose of Medication:
- Prevent pregnancy.
- Control symptoms related to menstruation.
- Clinical outcome: Most women experience lighter, shorter periods and decreased uterine cramps.
Core Cardiovascular Risk Summary:
- Estrogen increases blood clotting risks, directly predisposing patients to venous thromboembolism (VTE), myocardial infarction (MI), and stroke.
Pharmacological Mechanisms of Action
Estrogen Actions:
- Prevents the formation of a dominant follicle.
- Prevents ovulation.
- Prevents the luteinizing hormone (LH) surge.
- Stabilizes the uterine endometrium.
- Inhibits proliferation and secretory endometrial changes.
- Decreases irregular and/or heavy menstruation.
Progestin Actions:
- Balances the physiological effects of estrogen.
- Makes the endometrium less favorable for blastocyst implantation.
- Suppresses the LH surge.
- Prevents ovulation and pregnancy.
Adverse Effects and Hormonal Complications
Increased Estrogen Effects:
- Cyclic breast changes and tender breasts.
- Dysmenorrhea.
- Menorrhagia.
- Chloasma (hyperpigmentation).
- Venous Thromboembolism (VTE).
Decreased Estrogen Effects:
- Amenorrhea.
- Spotting.
Increased Progestin Effects:
- Weight gain.
- Depression.
- Fatigue.
- Decreased libido.
Decreased Progestin Effects:
- Breakthrough bleeding.
- Headaches.
Complications from Higher Estrogen Doses:
- Increased risk of myocardial infarction (MI).
- Increased risk of venous thromboembolism (VTE).
- Increased risk of stroke.
Contraindications, Precautions, and Drug Interactions
Contraindications & Precautions:
- Women older than who smoke: High risk of increased VTE.
- Drospirenone (Yasmin) Specific Contraindications:
- Liver insufficiency.
- Kidney insufficiency.
- Adrenal insufficiency.
- Long-term concurrent use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
- Long-term concurrent use with potassium-sparing diuretics.
- Long-term concurrent use with Angiotensin-Converting Enzyme (ACE) inhibitors.
- Long-term concurrent use with Angiotensin Receptor Blockers (ARBs).
Drug Interactions:
- Antibiotics: Can interfere with oral contraceptive efficacy; patients must use non-hormonal backup contraception while taking antibiotics.
- Yasmin + Potassium-Increasing Drugs: Concurrent use increases levels, posing a severe risk of hyperkalemia. Hyperkalemia can lead to lethal cardiac events, including ventricular arrhythmias and ventricular tachycardia (V-tach).
Administration Routes, Regimens, and Missed-Dose Protocols
General Administration Routes:
- Oral.
- Transvaginal.
- Transdermally.
Oral Contraceptive Regimens:
- Most common route worldwide due to ease of use.
- Supplied in or packs.
- Consists of of active hormone pills followed by either no pills or for the final .
- The last trigger withdrawal bleeding.
Transdermal Patch (Ortho-Evra):
- Application Sites: Stomach, buttocks, outer arm, or upper torso.
- Site Management: Sites must be rotated continuously. Skin must be clean, dry, and free from hair. Do not cut the patch.
- Schedule: Patch is worn for continuously, followed by off (withdrawal bleeding occurs).
- Weight Limitation: Reduced efficacy in women weighing more than .
Transvaginal Ring (NuvaRing):
- Structure: A indwelling flexible ring containing estrogen and progestin.
- Insertion Schedule: Inserted into the vagina during the first of menstruation. Remains in place for , then removed for off (withdrawal bleeding occurs).
- Displacement Protocol: If the ring falls out, it must be reinserted within . If out for more than , a backup contraceptive method must be used for .
Nursing Interventions for Missed Oral Pills:
- Miss : Take the missed tablet as soon as remembered.
- Miss : Take as soon as remembered, take the next day, and use backup non-hormonal contraception for the remainder of the cycle.
- Miss : Discard the pill pack entirely and restart.
Comparison of Ortho-Evra Transdermal Patch and NuvaRing

Ortho-Evra Patch Specifications:
- Route: Transdermal.
- Duration: .
- Off Period: .
- Main Concerns: Skin irritation, VTE, nausea, cramps.
- Smoking Hazard: Increased VTE risk.
- Weight Constraint: Less effective in patients exceeding .
NuvaRing Specifications:
- Route: Transvaginal.
- Duration: .
- Off Period: .
- Main Concerns: VTE, vaginal irritation, discharge/infection.
- Smoking Hazard: Increased VTE risk.
- Displacement Constraint: Replace within if displaced.
Clinical Efficacy, Therapeutic Uses, and Patient Education
Efficacy Rates:
- effective with absolute correct (perfect) use.
- effective with typical use.
- Crucial Limitation: CHCs do NOT protect against Sexually Transmitted Infections (STIs).
Evaluation of Medication Effectiveness:
- Prevention of pregnancy.
- Decreased menstrual blood loss.
- Decreased uterine cramps.
- Elimination of mittelschmerz (pain associated with ovulation).
- Reduction of irregular and/or heavy menstruation.
Non-Contraceptive Therapeutic Uses:
- Decreased blood loss and menstrual cramps.
- Elimination of mittelschmerz.
- Reduction of ovarian cysts.
- Reduction of benign breast disorders.
- Reduction of pelvic inflammatory disease (PID).
- Reduction of ectopic pregnancies.
Patient Education Guidelines:
- Reinforce that CHCs afford zero protection against STIs.
- Instruct patient to use secondary backup contraception if prescribed antibiotics.
- Adhere strictly to missed-dose protocols.
- Rotate transdermal patch sites and never cut a transdermal patch.
- Replace a fallen NuvaRing within or maintain backup contraception for .
- Warn patients that smoking significantly escalates VTE risk.
- Advise using the lowest possible estrogen dose to mitigate serious systemic adverse effects.
Classification of Estrogens and Progestin Generations
Estrogen Dosage Guidelines:
- Lower-estrogen formulations containing estradiol are preferred in modern clinical practice.
- Always utilize the lowest effective dose.
- Higher estrogen concentrations directly correlate with increased risks of MI, VTE, and stroke.
- Mestranol is a synthetic estrogen used primarily in older formulations or high-concentration products.
Generational Breakdown of Progestins:
- Generation: Norethindrone, Norethindrone acetate, Ethynodiol.
- Generation: Norethisterone, Levonorgestrel (LNG - most common progestin component).
- Generation: Desogestrel, Gestodene, Norgestimate.
- Generational Progression Trends: Higher progestin generations demonstrate higher contraceptive efficacy, fewer adverse metabolic/lipid impacts, and significantly reduced androgenic side effects.
Phasic Oral Formulations and Specific Contraceptive Products
Phasic Oral Categories:
- Monophasic: Contains a fixed ratio of estrogen and progestin throughout the entire active cycle.
- Biphasic: Features a fixed amount of estrogen with lower progestin levels early in the cycle, permitting normal physiological menstruation processes without ovulation (Example: Ortho-Novum).
- Triphasic: Delivers low total doses of estrogen and progestin with altered ratios across ; minimizes side effects (Example: Ortho Tri-Cyclen Lo, which is also indicated for acne treatment).
- Four-phasic: Delivers varying doses of estradiol valerate and dienogest across four distinct phases; newest class designed to closely mimic physiological hormone ratios.
Specific Brand Formulations & Clinical Profiles:
- Yasmin: Monophasic oral contraceptive consisting of ethinyl estradiol and drospirenone. Drospirenone is a spironolactone analogue with potassium-sparing properties, carrying a risk of hyperkalemia and secondary V-tach/ventricular arrhythmias.
- Loestrin FE: Formulated with supplemental iron () during the inactive pill period to combat iron-deficiency anemia from withdrawal bleeding.
- Mircette: Features of iron () and of low-dose estrogen during the off-period to prevent estrogen-withdrawal headaches.
Extended-Cycle and Continuous Formulations:
- Physiological Note: Withdrawal bleeding on CHCs is artificially induced and is not a true physiological menstrual period; it is not medically necessary.
- Extended-Cycle Products: Shorten inactive pill intervals to minimize total withdrawal bleeding days (Examples: Loestrin 24, YAZ, Beyaz).
- Continuous Dosing Products:
- Seasonale / Jolessa: regimen composed of followed by , resulting in withdrawal bleeding only .
- Lybrel: continuous active formulation that eliminates withdrawal bleeding entirely.